Meeting
2024 ASCO Breakthrough
Association between the occurrence of immune-related adverse events and survival outcomes in patients with cancer treated with perioperative immune checkpoint inhibitors: A systematic review and meta-analysis.
Authors
Taiga KOMATSU
St. Luke's International Hospital, Chuo-Ku, Japan
Taiga KOMATSU , Kohei Chida , Nobuyuki Horita , Alessio Cortellini , Abdul Rafeh Naqash , Yu Fujiwara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Immunotherapies
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 39)
DOI
10.1200/JCO.2024.42.23_suppl.39
Abstract #
39
Poster Bd #
B2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non–small cell lung cancer and melanoma.
First Author: Sharjeel Syed
Poster
2022 ASCO Annual Meeting
The prognostic impact of immune-related adverse events in real-world patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade.
First Author: Alexander Watson
Poster
2021 ASCO Annual Meeting
A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types.
First Author: Alberto Puccini
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Immune-related adverse events (irAE) to cancer immune checkpoint inhibitors (CPI) and survival outcomes: To rechallenge or not–An Appalachian institution’s experience.
First Author: Heidar Albandar